

ABSTRACT/POSTER DIRECTORY

101	Modulation of the Hepcidin Pathway Produces Homogeneous Erythropoietic Suppression but Heterogeneous Iron Repletion in Polycythemia Vera: Lessons from REVIVE and IMPRSSION.	12
102	Factors Associated With Treatment Failure in Chronic Myeloid Leukemia Monitored by GeneXpert BCR-ABL1 in Senegal	13
103	Progressive Loss of Negative Charge in the CALR C-Terminus Redefines the Mechanism of CALR-Mutant Myeloproliferative Neoplasms and Expands the Spectrum of Pathogenic CALR Mutations	15
104	Pattern of PDGFRA Gene Rearrangement in Clinically Suspected Myeloproliferative Neoplasms With Eosinophilia	17
105	Spectrum of Molecular Markers in Chronic Myeloproliferative Neoplasms Among Pakistani Patients	18
106	Global Assessment of Patient Unmet Needs in Myeloproliferative Neoplasms: Findings From the 2026 International Assessment	19
107	Shared Abnormalities in Idiopathic Pulmonary Fibrosis (IPF) and Myelofibrosis (MF) Decrease Translation of GATA1 and Cause Megakaryocyte (MK) Dysfunction	21
108	Preliminary Data Supports the Feasibility of the MPN PROGRESSion Registry® as a Real-World Evidence (RWE) Platform for Studying MPN Disease Progression With EMR and PRO Data	22
109	Spectrum of BCR::ABL1 Kinase Domain Mutations Associated with Imatinib Resistance in Philadelphia-Positive Leukemia: A Tertiary-Care Experience from Pakistan	25
110	MYELOVAC: A Phase I Trial of a Personalized Peptide Neoantigen Vaccination Platform in Combination With Hypomethylating Agent-Based Therapy for Patients with Acute Myeloid Leukemia in First Complete Remission Ineligible for Intensive Chemotherapy and Allogeneic Stem Cell Transplantation	26
111	Initial Results From an Ongoing Phase 2 Open-Label Study Investigating DISC-3405, a Novel Anti-TMPRSS6 Monoclonal Antibody, in Participants With Polycythemia Vera (RESTORE-PV)	27
112	Real-World Experience of Ropeginterferon Alfa-2b in Chinese Patients With Myeloproliferative Neoplasms: A Multicenter Retrospective Analysis of 87 Cases	28
113	Discovery and Characterization of DMR-001, a Highly Potent, Pan-Mutant, Long-Acting, Fc-Null Monoclonal Antibody Targeting Mutant Calreticulin	29
114	Additional Chromosomal Abnormalities in Chronic Myeloid Leukemia Patients- Data From a Tertiary Care Center in Pakistan	30
115	VECTRA: A Phase 2 Study of Dencatostat, a First in Class Oral CTPS1 Inhibitor, for the Treatment of High Risk Essential Thrombocythemia	31
116	Projected Budget Impact of Once-Daily Extended-Release Versus Twice-Daily Immediate-Release Ruxolitinib Through Adherence-Associated Reductions in Healthcare Resource Utilization	32
117	Givinostat Attenuates the Polycythaemia Vera Phenotype in a JAK2 ^{+/V617F} Mouse Model	33
118	Long-Term Outcomes Following First-Line Hydroxyurea in Polycythemia Vera and Essential Thrombocythemia: A Systematic Review and Meta-Analysis	34
119	You and MPN: Reach, Self-Reported Knowledge Gain, and Intended Actions Following an Animated Patient Education Program for Myeloproliferative Neoplasms	37
120	Competitive GFI1B-SPI1 Occupancy at the Helios Enhancer Promotes Leukemic Transformation in Chronic Myeloproliferative Neoplasm	40

Abstracts are not CME accredited.

121	Inflammation and Thrombosis in Myeloproliferative Neoplasms: Real-World Evidence for Autoimmune Disease as a Modifiable Risk Factor	43
122	Imetelstat Plus Ruxolitinib in Patients With Intermediate-1/2 or High-Risk Myelofibrosis: Updated Results From the IMproveMF Trial	44
123	Mutant Calreticulin-Specific Monoclonal Antibody, INCA033989, Produces Clonal Molecular Responses That Correlate With Clinical Responses in Patients With Myelofibrosis	45
124	Long-Term Bone Health Outcomes in Patients Treated With Avapritinib for Indolent Systemic Mastocytosis: Findings From the PIONEER Study	47
125	Long-Read RNA-Seq Uncovers a Novel Splice Isoform of <i>YBX1</i> Implicated in <i>SRSF2</i> Mutated CMML	48
126	Does Pre-Existing Depression or Anxiety Preclude Ropoginterferon Alfa-2b in Polycythemia Vera and Essential Thrombocythemia?: A Real-World Multicenter Cohort Study	51
127	Durable Complete Molecular Responses After Ropoginterferon Alfa-2b Discontinuation in Polycythemia Vera: A Three-Case Series With up to More Than 5 Years of Treatment-Free Remission	53
128	Noninvasive Assessment of Myelofibrosis-Associated Fibrotic Burden by CCR2-Targeted Functional Imaging: Evidence from the Gata1 ^{low} Mouse Model	55
129	Clinical Phenotype and Outcomes of <i>CALR</i> Mutation Subtypes in Myelofibrosis	56
130	Outcomes after Non-Myeloablative Total Body Irradiation (TBI)-Based Conditioning Platform With Post-Transplant Cyclophosphamide in Hematopoietic Cell Transplantation (HCT) for Myelofibrosis	58
131	Momelotinib Outcomes in Patients with Intermediate-1– vs Intermediate-2–/High-Risk Myelofibrosis: Post Hoc Analyses of the Phase 3 SIMPLIFY-1 and MOMENTUM Trials	59
132	Characterization of Symptoms After Immediate Transition From Ruxolitinib to Momelotinib in Patients With Myelofibrosis: Post Hoc Analyses of the Phase 3 SIMPLIFY-1 and SIMPLIFY-2 Trials	61
133	SGLT2 Inhibitor Exposure and Thrombotic and Hematologic Outcomes in Polycythemia Vera: A TriNetX Retrospective Cohort Study	62
134	Exploiting DNA Damage Vulnerabilities in MPN: Clinical Experience with JAK2 and PARP Inhibition	64
135	Incidence of Arterial Thromboembolism in Patients With Myeloproliferative Neoplasms Treated With Anticoagulation for Venous Thromboembolism	66
136	Pretreatment Bone Marrow Histotopography Predicts Molecular Response in <i>JAK2</i> V617F-Positive Polycythemia Vera and Essential Thrombocythemia	68
137	Incremental Prognostic Value by Functional Grouping of Signaling and Non- <i>CUX1</i> Transcription Mutations in Overt Primary Myelofibrosis	69
138	Impact of Rapid versus Slow Titration of Ropoginterferon alfa-2b on <i>JAK2</i> V617F Allele Burden in Japanese Patients with Polycythemia Vera	71
139	Association of Hematocrit Control With Thrombotic Risk in Polycythemia Vera – A Systematic Literature Review and Meta-Analysis	73
140	Real-World Characteristics and Treatment Patterns Among Patients Initiating First-Line Ropoginterferon Alfa-2b or Other Cytoreductive Therapies for Polycythemia Vera	75

Abstracts are not CME accredited.

ABSTRACT/POSTER DIRECTORY

141	Patient Experiences in Essential Thrombocythemia: Insights into Diagnosis, Disease Burden and Treatment Unmet Needs from a U.S. Qualitative Study	76
142	A Phase 3, Double-Blind, Randomized Trial Evaluating the Efficacy and Safety of Elritercept Versus Placebo in Patients With Myelofibrosis and Anemia on Concurrent Ruxolitinib Therapy: The ELRISE MF Study Design	78
143	Update From the Phase 2 RESTORE Trial of Elritercept in Patients With Myelofibrosis Receiving Ruxolitinib	79
144	Healthcare Provider Perspectives on the Phlebotomy Workflow in Polycythemia Vera and Associated Resource Use in the United States	80
145	Impact of Rusfertide on Polycythemia Vera (PV)-Related Symptoms and Patient-Reported Outcome-Related Items in the Randomized, Double-Blind Phase 3 VERIFY Study	81
146	Real-World Treatment Patterns and Outcomes in Patients With Myelofibrosis Treated First-Line With Pacritinib or Ruxolitinib	83
147	Consistency of Response by Baseline Platelet Count in Pacritinib-Treated Patients in the Real World: MY-PAC Analysis	85
148	A Phase 2 Study of the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral Epetraborole Tablets for the Treatment of Adults with Phlebotomy-Dependent Polycythemia Vera	87
149	Effect of Rusfertide on Cytoreductive Therapy Use in Patients With Phlebotomy Dependent Polycythemia Vera: Post Hoc Analysis From the Randomized Controlled Phase 3 VERIFY Study	89
150	Disease Modification Biomarker Changes in Patients With Myelofibrosis Treated With Selinexor Plus Ruxolitinib	91
151	The Effect of Bezucastinib on the Pathobiology of Mastocytosis: Changes in BM Mast Cells, Tryptase, and <i>KIT</i> p.D816V Variant Allele Frequency from the Pivotal Summit Trial	94
152	The Effect of Bezucastinib on the Pathobiology of Advanced Systemic Mastocytosis: Results From the Pivotal Apex Trial	95
153	Expanded Results From the Phase 2 Summit Trial: Bezucastinib in Adults With Nonadvanced Systemic Mastocytosis	96
154	Evaluation of Bone Formation Marker Changes in Summit, a Trial Assessing Bezucastinib in Adults With Non-Advanced Systemic Mastocytosis: An Exploratory Analysis	97
155	Efficacy and Safety of Bezucastinib in Patients With Advanced Systemic Mastocytosis: Results From the Apex Study	98
156	Improvement of Symptom Burden in Summit: Bezucastinib in Adults with Nonadvanced Systemic Mastocytosis	99
157	Results of LY5830966 (AJX-101), a Phase 1 Clinical Trial of the Type II JAK2 Inhibitor AJ1-11095, in Patients With Myelofibrosis Who Have Been Failed by a Type 1 JAK2 Inhibitor	100
158	Anemia Response With Imetelstat in Patients With Myelofibrosis From IMbark per Updated Clinical Criteria	101
159	Associations With Lactate Dehydrogenase and Clinical Outcomes in Patients With Myelofibrosis With and Without Ruxolitinib Treatment: Post Hoc Analyses of COMFORT-I and COMFORT-II	103
160	Spleen Volume Response to Ruxolitinib Across Baseline Hemoglobin Subgroups in Patients With Myelofibrosis and Anemia: A Pooled Analysis of COMFORT-I and COMFORT-II	104
161	Real-World Treatment Patterns and Unmet Needs in Essential Thrombocythemia From US Claims Data	106
162	Age-Based Differences in Ropeginterferon Alfa-2b Utilization and Treatment Persistence in Polycythemia Vera: Real-World Evidence from US Claims Data	108

Abstracts are not CME accredited.

163	Real-World Treatment Patterns and Clinical Outcomes in Patients With Essential Thrombocythemia Treated With Cytoreductive Therapy in the U.S.	109
164	A Phase 1 Study of PRT12396, a JAK2 V617F Mutant-Selective Inhibitor, in Patients With Polycythemia Vera or Myelofibrosis	111
165	Real-World Validation of Survival Benefit Associated With Interferon Alfa Use in Myelofibrosis	113
166	Cytoreduction in Adolescent and Young Adult Patients With Polycythemia Vera and Essential Thrombocythemia: Indications, Agent Selection, and Durability	115
167	Comparative Safety of Anticoagulants in Patients With Myeloproliferative Neoplasms and Venous Thromboembolism: A Retrospective Cohort Study	116
168	Concurrent FLT3-ITD in Myelodysplastic/Myeloproliferative Neoplasm With SF3B1 Mutation and Thrombocytosis: A Case Report	117
169	Concurrent Molecular Drivers in Myeloproliferative Neoplasms: Recognizing Synchronous <i>BCR::ABL1</i> and <i>JAK2</i> , <i>CALR</i> or <i>MPL</i> Alterations	119
170	Evaluation of the Association Between Variant Allele Frequency of Mpn Driver Genes (<i>JAK2</i> , <i>MPL</i> and <i>CALR</i>) and the Risk of Thrombosis	120
171	Second Solid Malignancies and Survival in Patients With Chronic Myeloid Leukemia by Early Documented Tyrosine Kinase Inhibitor Exposure: A Large Real-World TriNetX Cohort Analysis	121
172	HMGA1 Chromatin Regulators Disrupt 3D Genome Architecture and Chromatin Looping to Repress Antigen Presenting Genes and Drive Immune Evasion during MPN Progression	122
173	HMGA1 Chromatin Regulators Activate Transcriptional Networks Involved in Megakaryocyte Expansion, Fibrosis, and Sensitivity to Interferon- α Therapy in <i>JAK2</i> ^{V617F} MPN	124
174	Healthcare Resource Utilization and Costs Among Patients With Essential Thrombocythemia Who Develop Resistance or Intolerance to Hydroxyurea in the US	126